Human mesenchymal stem cell therapy in severe COVID-19 patients: 2-year follow-up results of a randomized, double-blind, placebo-controlled trial

BACKGROUND: Long-term effects of human mesenchymal stem cell (MSC) treatment on COVID-19 patients have not been fully characterized. The aim of this study was to evaluate the safety and efficacy of a MSC treatment administered to severe COVID-19 patients enrolled in our previous randomized, double-b...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Tian-Tian, Zhang, Bo, Fang, Hui, Shi, Ming, Yao, Wei-Qi, Li, Yuanyuan, Zhang, Chao, Song, Jinwen, Huang, Lei, Xu, Zhe, Yuan, Xin, Fu, Jun-Liang, Zhen, Cheng, Zhang, Yu, Wang, Ze-Rui, Zhang, Zi-Ying, Yuan, Meng-Qi, Dong, Tengyun, Bai, Ruidan, Zhao, Lulu, Cai, Jianming, Dong, Jinghui, Zhang, Jianzeng, Xie, Wei-Fen, Li, Yonggang, Shi, Lei, Wang, Fu-Sheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161678/
https://www.ncbi.nlm.nih.gov/pubmed/37149930
http://dx.doi.org/10.1016/j.ebiom.2023.104600

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10161678/
https://www.ncbi.nlm.nih.gov/pubmed/37149930
http://dx.doi.org/10.1016/j.ebiom.2023.104600

Ejemplares similares